Rachlin Evan Lockwood
SEC Form 4 insider trading activity
Rachlin Evan Lockwood has filed 1 SEC Form 4 filing (4 transaction rows) across 1 company, with disclosures dating back to 2026. 1 of those filings fall inside the rolling window. Most recent filing: Oct 19, 2026.
On the most recent filing, Rachlin Evan Lockwood is listed as Director at Iambic Therapeutics, Inc. Inside the rolling window, Rachlin Evan Lockwood reported 1 open-market purchase totaling $11.5M in IAM and no open-market sales.
Companies traded
Other insiders at IAM
Insider Buying
$11.5M
reported purchases (SEC code P)
Insider Selling
$0
reported sales (SEC code S)
Companies
1
in the rolling window
Frequently asked questions
How many SEC Form 4 filings has Rachlin Evan Lockwood made?
Rachlin Evan Lockwood has filed 1 SEC Form 4 filing (4 transaction rows) across 1 company since 2026.
Which companies does Rachlin Evan Lockwood trade?
Rachlin Evan Lockwood has filed SEC Form 4 disclosures for 1 company, including IAM.
When was Rachlin Evan Lockwood's most recent SEC Form 4 filing?
Rachlin Evan Lockwood's most recent SEC Form 4 filing on Tracefour is dated Oct 19, 2026.
What is Rachlin Evan Lockwood's total buy and sell value in the current window?
Inside the rolling retention window, Rachlin Evan Lockwood bought $11.5M and sold $0 based on SEC Form 4 filings.
What was Rachlin Evan Lockwood's largest disclosed transaction?
The largest disclosed transaction in the current window is a purchase of 718,750 IAM shares on 2026-10-16, worth $11.5M, per SEC Form 4 filings.